# GHK-Cu: the remodeling signal that is part of the matrix it rebuilds > GHK-Cu — Recovery & Tissue Repair Research Peptides — renovapeptides — GHK-Cu among the Recovery & Tissue Repair research peptides: a copper tripeptide whose sequence sits inside type I collagen, studied for matrix synthesis, metalloproteinase balance and cross-linking. Cited findings and stated limits. **LATE PHASE — MATRIX & CROSS-LINKING** Three amino acids carrying one copper ion. The sequence occurs inside type I collagen; the documented job is building matrix and governing how fast matrix is taken apart again. ## Start here GHK-Cu is one of the smallest molecules with a serious research file behind it: three amino acids — glycine, histidine and lysine — holding a single copper ion. The peptide half is not synthetic in origin. That exact three-letter sequence occurs inside the alpha-2(I) chain of type I collagen, the main structural protein of skin, tendon and bone, and inside SPARC/osteonectin, another matrix protein. A signal for rebuilding matrix is, quite literally, written into the matrix. In plain terms, copper is a required helper for enzymes that build and cross-link the body's structural fibres, and GHK acts as its carrier and as a signal in its own right. Cells exposed to it make more collagen and more of the gel-like material that fills the space between fibres [4]. Free GHK also circulates in blood, and the amount falls with age — from roughly 200 ng/mL at twenty years old to about 80 ng/mL by sixty [4]. That decline is the most-quoted fact about this peptide, and it deserves a careful reading: a falling signal is an observation, not a demonstrated cause of ageing tissue. ## What GHK-Cu is GHK-Cu is a linear tripeptide, glycyl-L-histidyl-L-lysine, chelated one-to-one with a copper(II) ion. The metal is held through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen and the deprotonated glycine-histidine amide nitrogen, leaving the lysine side chain free. That geometry is not a chemical footnote. It binds copper tightly, and tight binding is what keeps the metal from behaving as a loose pro-oxidant — the intact complex is described as blocking certain oxidation reactions rather than driving them. If a product degrades, or is mixed with something that strips the copper away, that protection is lost and free copper can promote oxidation instead. Two names for two different things are worth separating here, because the literature routinely blurs them. **GHK** is the bare tripeptide. **GHK-Cu** is the copper complex. Most of the documented tissue-remodeling activity depends on the copper actually being bound; the plain peptide fails to reproduce key effects, including metalloproteinase-2 stimulation, in cell studies. Whenever a claim is made for "GHK", the first question is which form was tested. In cosmetics the complex appears as Copper Tripeptide-1. In research supply it also travels under copper peptide GHK-Cu, GHK copper complex, prezatide copper and tripeptide-1 (copper). ## Where it acts in the repair sequence Repair finishes with remodeling, and remodeling is a balance between synthesis and controlled demolition. GHK-Cu is documented on both sides of that balance, which is unusual. On the synthesis side, at picomolar-to-nanomolar concentrations it stimulates dermal fibroblasts to produce collagen, elastin, glycosaminoglycans and the small proteoglycan decorin [4]. On the demolition side, it rebalances matrix metalloproteinases against their TIMP inhibitors, so that turnover proceeds without running away. The copper it delivers is required by lysyl oxidase, the enzyme that cross-links collagen and elastin into fibre capable of bearing load, and supports a superoxide-dismutase-like antioxidant activity. A broader tissue-remodeling review extends the picture well past the skin: GHK-Cu increases collagen, elastin, metalloproteinases and anti-proteases, VEGF, FGF-2 and nerve growth factor, while suppressing free radicals and the signalling proteins TGF-beta-1 and TNF-alpha, and chemoattracts repair cells into injured tissue [9]. That is a compound acting at several points in the sequence rather than through a single receptor — which is a strength for a remodeling story and a weakness for a clean mechanistic one. Its documented cellular targets run correspondingly wide: keratinocytes, hair-follicle dermal papilla cells, vascular endothelial cells, lung fibroblasts, intestinal epithelium and neurons all appear in the literature. Gene-expression work pushes the claim further still, and needs its caveat carried alongside it — which is the next section's job. ## What the studies measured **Matrix synthesis, in people.** The most-cited human comparison is a procollagen result. A 2025 review of topically applied GHK reports procollagen synthesis increased in 70% of GHK-Cu-treated subjects, against 50% for vitamin C and 40% for retinoic acid [1]; the canonical skin-regeneration review reports the same comparison in treated women, alongside placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density [4]. **Delivery, quantified.** A human skin-penetration study measured copper applied as the GHK-Cu tripeptide crossing dermatomed skin with a permeability coefficient of 2.43 plus or minus 0.51 x 10^-4 cm/h. Over 48 hours, 136.2 plus or minus 17.5 micrograms per square centimetre of copper permeated, and 97 plus or minus 6.6 micrograms per square centimetre was retained in the dermis as a depot [5]. The depot is the detail that matters on a remodeling site: it describes a reservoir feeding a slow process rather than a spike passing through. **The barrier problem.** Free GHK is strongly water-loving — a calculated logP of -2.24 — which is close to the worst possible profile for crossing the skin's waxy outer layer. Much recent work is therefore about formulation rather than biology: a palmitoylated version raises calculated logP to 1.14, and microneedle pretreatment allowed roughly 134 nmol of GHK to permeate where intact skin allowed none [1]. **Hair.** The strongest controlled human signal belongs to a combination, not to the peptide alone. Over six months in 45 men with androgenetic alopecia, a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 at one concentration and 71.5 at another, against 9.6 for placebo, with no adverse events in any group [3]. A real result, and one that cannot isolate the peptide's own contribution. **Gene expression, with the caveat attached.** GHK modulates expression of approximately 31.2% of human genes at a 50%-or-greater change threshold, raising 59% of the affected genes and suppressing 41%, with strong stimulation of the ubiquitin-proteasome system — 41 genes up, one down — and of DNA-repair and antioxidant gene sets [2]. For a site about remodeling, the protein-clearance half of that is the interesting half: turnover requires disposal as much as it requires synthesis. The widely repeated "about 4,000 genes" figure is an extrapolation; the table at that threshold reports on the order of 2,100 genes, and the analysis derives largely from database work that still needs protein-level validation in living tissue. ## What users report — and what the safety record says What follows first is community-reported material: **anecdotal, not clinical evidence**. It is drawn from skincare forums, product-review pages and community guides, describes topical cosmetic use unless stated otherwise, and carries no verified dose. Firmer, more elastic-feeling skin is the single most common thing people say they are after, described as building gradually over several weeks of consistent use rather than appearing overnight. Softer fine lines and shallower-looking wrinkles come up just as often, usually on a six-to-twelve-week horizon and framed as cumulative. Better hydration and a plumper look tend to be reported earliest, within the first week or two. Smoother texture and a brighter appearance are frequent. More even tone and faded marks are reported occasionally and in both directions. Calmer-looking skin after cosmetic procedures and on healing scars is an occasional theme, described as supportive rather than curative. On the scalp, less shedding within one to two months and denser-looking hair over three to six months is frequently described, with community consensus treating it as an add-on rather than a stand-alone treatment. A smaller group describes reconstituting GHK-Cu for injection and reports skin-quality or recovery changes; those accounts sit outside the documented topical use and have no validated human data behind them at all. The reported downsides are consistent. Irritation — redness, itching, stinging, a dry tight feeling — is the most common complaint, especially on sensitive skin and at higher strengths. Breakouts or a "purging" phase are occasionally described. A minority report pigment looking darker or patchier rather than more even. Rarely, users describe skin looking duller instead of better. And a very common practical complaint is loss of effect, or added irritation, when copper peptides are layered with pure vitamin C, strong acids or retinol in the same step. The documented cautions track those reports and then extend past them. Copper supports tyrosinase, the enzyme that drives melanin production, and a laboratory study found a copper peptide raised tyrosinase activity and melanin in pigment-cell lines — which is why people with melasma or stubborn dark spots are commonly advised to be cautious. Strong reducing agents at low pH and exfoliating acids can break the copper-peptide complex apart, wasting both products and stacking irritation; the peptide is most stable at mildly acidic-to-neutral pH. Systemically the picture is thinner and more serious. Injectable use is unapproved and has no validated human pharmacokinetic basis; the nearest data is a rat study showing the free peptide is cleared quickly from the bloodstream, so community injection protocols rest on nothing published. Repeated systemic copper delivery raises a mechanism-based, theoretical concern about copper and zinc balance that matters most for people with copper-handling conditions such as Wilson's disease — no human copper-toxicity case attributed to GHK-Cu appears in the peer-reviewed record, and rodent work stayed below copper-overload thresholds. And the broadest caution is about proportion: the sweeping anti-ageing claims rest largely on cell, rodent and database studies from a limited number of groups, while the controlled human evidence stays small and topical [1][4]. ## Where GHK-Cu sits in the repair timeline GHK-Cu is the late-phase entry on this desk and the best-evidenced one, and both halves of that sentence have to be held at once. It is the ingredient that gives the [GLOW blend](/glow) its matrix rationale, and the only compound here with placebo-controlled human data behind a measured endpoint. It is also a compound whose broadest claims — genome-scale rejuvenation, systemic anti-ageing — rest on mechanistic and database work, while the controlled human record remains small topical trials and one combination hair study [3]. The honest summary is narrow and real. Within the remodeling phase, applied topically, GHK-Cu measurably shifts what fibroblasts build and how matrix turnover is balanced. By any route other than topical, it is an unapproved research compound with no human pharmacokinetics at all. [Set against the other two entries](/compare), it is the one whose main risk in ordinary use is irritation rather than anything systemic — and the one whose evidence, though modest, was actually collected in people. --- renovapeptides is an independent reading desk for the tissue-repair literature: every figure here traces to a listed study, and none of it is a product, a protocol, or clinical advice.